Researchers design a pioneering drug capable of reversing cognitive decline in Alzheimer’s disease in animal models

The research team included professors Christian Griñán Ferré and Mercè Pallàs Lliberia, along with researchers from UBneuro, CIBERNED, IBUB, INSA-UB, IDIBAPS and other national and international institutions.

"The FLAV-27 compound represents an innovative and promising approach for Alzheimer's, with the potential to modify the disease, since it does not act only on its symptoms or a single pathological biomarker, but directly on its underlying molecular mechanisms," explains Aina Bellver Sanchis, researcher at the Institute of Neurosciences of the UB (UBneuro) and first author of the work.

More